Why is CVS Health stock up 2.6% today?

Traders Union
All News
Stocks
CVS Health rises 2.67% today

Highlights

CVS Health will split its retail pharmacy unit from insurance and pharmacy services to create two public companies by early 2028.
Third-quarter 2026 revenue exceeded $108 billion and adjusted earnings beat estimates, prompting an increase to full-year guidance with at least $6.98 in GAAP EPS projected.
CVS Health stock trades below key moving averages with sellers dominating momentum; price is expected to range from $76.25 to $90.77 with 77% probability of a downward move.

Restructuring and strong results drive guidance upgrade and credit aims

CVS Health Corp revealed it will separate its retail pharmacy arm from its insurance and pharmacy services businesses, aiming to create two publicly traded entities by the first half of 2028. This announcement came together with strong third-quarter 2026 results, as revenue exceeded $108 billion and adjusted earnings surpassed expectations. The company also raised its full-year 2026 guidance and projected GAAP diluted EPS of at least $6.98 while affirming that each new entity is expected to maintain an investment-grade credit profile.

Anton Kharitonov, expert at Traders Union, sees CVS’s move to separate its businesses as high risk despite the upbeat results. He notes the stock remains under pressure, trading below all significant moving averages. Technicals warn of ongoing seller dominance, with momentum and sentiment indicators confirming weakness. The raised outlook may offer some relief, but structural concerns linger amid persistent volatility. "The separation plan does little to offset bearish signals, so I remain cautious on CVS’s near-term prospects."

Viktoras Karapetjanc, expert at Traders Union, highlights the value-creating potential of CVS’s business split and strong earnings. He points out that both new entities are set for investment-grade credit, which supports investor confidence. The bullish structure remains intact despite short-term selling, as raised guidance and better-than-expected revenue lay groundwork for future growth. Karapetjanc believes market offers ample setups once resistance breaks. "With structural reforms underway and financials outpacing expectations, further upside for CVS is likely as market digests these catalysts."

Parshwa Turakhiya, analyst, notes that sentiment is split even after CVS’s positive news and separation plans. Technical indicators show sellers control moves for now, but oversold signals could spark short-term rebounds. Price action near resistance creates opportunity for active traders, especially if volatility persists. "If $84.34 breaks on volume, I see a window for quick gains before sellers reassert control."

Long-term bullish bias as sellers pressure key technical levels

CVS is trading below its 20-day ($90.05), 50-day ($90.56), and 200-day ($88.89) moving averages, reflecting persistent selling pressure across timeframes. The nearest resistance is at $84.34, with support at $80.69. Longer-term technical structure remains bullish with the 50-day average above the 200-day, though momentum is dominated by sellers. MACD and ADX are both bearish, RSI reads neutral, and both Stochastic RSI and CCI are in oversold territory. Bull/Bear Power stays negative, indicating sellers control intraday moves. Price is near session highs despite ongoing momentum pressure and elevated volatility of 4.52%.

Previously it was reported that CVS planned to split into two independent, publicly traded companies by 2028 in response to mounting regulatory pressure on integrated healthcare models. The current technical setup suggests traders should closely monitor the $84.34 resistance, as a decisive move above this level could signal a potential shift away from the prevailing downside risk.

Source of Data: CVS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.